News

Everyone in the market has been talking about the explosive growth of the free mobile app, MyFitnessPal, blaming it for their poor results. Marketdata contacted the head PR person at MyFitnessPal to get some clarification of this huge number being quoted. As we thought, the 40 million is NOT the current number of active users. […]

This drug works by targeting the body, not the mind, and unlike rivals tthat suppress appetite, Zafgen’s drug, beloranib, is designed to make the body produce less fat and burn off the excess as fuel. “This is in contrast with other agents that really only affect hunger, and don’t actually restore balance of the fat,”

Gee what a surprise! Nestle, in its latest quarterly report, says that Jenny Craig has not been doing well for two years, and has a turnaround plan for it. No details yet, although we at Marketdata can’t wait to hear what it could possibly be. We’ve been saying that, although Nestle does not release financials

OK, all the 2nd quarter results are in for the publicly owned diet companies, and it’s bad across the board. Q2 was terrible. Plus, lots of top management changes. Weight Watchers: CEO resigns. Trouble over group leaders low pay. Revenues down 3.9% in Q2 and down 3.5% for first half of 2013. WW.com growth slows

Medifast said its net income more than doubled and sales grew 4%. Revenue from its Take Shape for Life MLM coaching unit rose 10%, which made up for lower sales from the company’s web site and phone orders and from company owned stores and wholesale physicians. The company has 86 corporate-owned locations and said Tuesday

The company today (Aug. 5) announced the appointment of tabloid content writer John McGran as Chief Editor along with health professional and registered dietitian Susan Burke March as Chief Nutritionist. Mr. McGran and Ms. March join the eDiets team as prior employees of the company, marking the brand’s transition back to a tabloid approach to

Marketdata Commentary – Lots of Questions, No Answers * Why did David Kirchoff abruptly resign, after 14 years with the company? No advance warning, not even 30 days? Troubling. Did he simply give up on the company after seeing that things are just not working? * Why isn’t management talking about the compensation situation with

Arena reported $1.3 million in Belviq net product sales in the second quarter, which is 31.5% of the $4.1 million in net product sales recorded by Eisai. Belviq hit pharmacy shelves in the beginning of June, so it’s only about a month of sales in the second quarter. Still, $4.1 million in net product sales

Highlights: Revenues for the quarter were $97.5 million and operating income was $9.8 million, both of which were in line with the company’s expectations; Adjusted EBITDA for the quarter was $13.5 million. Adjusted EBITDA is defined as net income excluding non-cash employee compensation, interest, income taxes, depreciation and amortization; Net income for the quarter was

Last Fall, Vivus botched the commercial launch of its Qsymia prescription weight loss pill and is now fighting off a dissident shareholder, First Manhattan, which wants to replace the company’s board of directors and management team. For Arena, the first few weeks of prescription data reported for the early Belviq launch have done nothing to